ChemBriefBiogen Beats Quarterly Estimates as Newer Drugs Fuel Growth
Biogen reported Q2 profits exceeding estimates driven by rare-disease medicines and Leqembi sales, though legacy MS drug revenue declined. The company cut its 2026 profit forecast following an $5.6 bi
reuters · 2026-07-29 03:03